Neumora Therapeutics Inc (NASDAQ:NMRA)’s traded shares stood at 1.12 million during the last session, with the company’s beta value hitting 2.82. At the close of trading, the stock’s price was $0.92, to imply a decrease of -9.64% or -$0.1 in intraday trading. The NMRA share’s 52-week high remains $17.19, putting it -1768.48% down since that peak but still an impressive 33.7% since price per share fell to its 52-week low of $0.61.
Analysts have given a consensus recommendation of Buy for Neumora Therapeutics Inc (NMRA), translating to a mean rating of 2.25. Of 3 analyst(s) looking at the stock, 0 analyst(s) give NMRA a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy.
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
After registering a -9.64% downside in the last session, Neumora Therapeutics Inc (NMRA) has traded red over the past five days. The 5-day price performance for the stock is 16.67%, and 33.10% over 30 days. With these gigs, the year-to-date price performance is -91.30%.
The extremes give us $2 and $4 for target low and target high price respectively. As such, NMRA has been trading -334.78% off suggested target high and -117.39% from its likely low.
NMRA Dividends
Neumora Therapeutics Inc has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is SOFTBANK GROUP CORP. with 7.65 million shares, or about 4.8099% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $75.17 million.
